GHRH analogue (with or without Drug Affinity Complex)
CJC-1295
Growth-hormone-releasing hormone analogue that stimulates pituitary GH secretion; DAC modification prolongs half-life via albumin binding.
Primary Mechanism of Action
Clinical / Scientific
CJC-1295 analogues activate the GHRH on pituitary somatotrophs, increasing GH pulse amplitude. The DAC (Drug Affinity Complex) maleimide derivative binds albumin and extends duration; “no DAC” versions more closely resemble shorter-acting GHRH fragments (often paired with GHRP/ipamorelin in research blends).
Pathway Targets
GHRH receptor
Scientific explanation
Pituitary agonism increasing GH release.
GH / IGF-1 axis
Scientific explanation
Downstream endocrine cascade.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GHRH receptor → GH / IGF-1 axis
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GHRHR | Agonism | GH secretion | Established mechanism (analogue pharmacology) |
Mechanistic Interaction Considerations
Additive GH-axis stimulation with GHRPs, tesamorelin, or exogenous GH is expected. Glucose handling, oedema, and IGF-1-related risks follow GH biology.
In Plain Language
CJC-1295 is a longer or shorter copy of the brain hormone that tells the pituitary to release growth hormone. The “DAC” version sticks to albumin so it lasts longer.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
GHRH receptor
GH / IGF-1 axis
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.